Search for other works by this author on: ...

Search for other works by this author on: ...

University of Nebraska Medical Center, Omaha, NE, ...

Adding the PD-1 inhibitor pembrolizumab to chemoradiotherapy for high-risk, locally advanced cervical cancer significantly improves patients’ overall survival compared to treatment with CRT alone.

Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...

According to the phase IIIb/IV DESTINYBreast-12 Trial, the results of which were presented at the European Society for Medical Oncology 2024 Congress in Barcelona, Spain, and concurrently published, ...

Copyright held by the owner/author(s).

Two HER2-targeted tyrosine kinase inhibitors, BAY 29270078 and zongertinib, each showed robust efficacy and safety in early phase. Patients experienced significant tumor shrinkage rates, and the ...

The FDA approved the PD1 inhibitor atezolizumab plus hyaluronidase (Tecentriq Hybreza; Genentech), which helps the drug move into tissues, as a subcutaneous injection for the same adult indications as ...

Cancer drug shortages continue to disrupt care for children, underscoring vulnerabilities in the pharmaceutical supply chain. Economic pressures on drug manufacturers highlight the need for more ...

Major Finding: Post-fast refeeding contributes to Lgr5 + intestinal stem cell proliferation and tumor formation. Concept: An mTORC1–polyamine–protein synthesis axis drives refeeding-associated ...